Shop

The Washington Monthly reports "By January 1997, the Food and Drug Administration's files were loaded with enough warning signs (of side effects) to have kept Rezulin out of the hands of unsuspecting diabetic patients....The FDA by (March 1999) was in the midst of an extraordinary re-evaluation of Rezulin, undertaken in response to a series of articles that (Willman) had authored for the Los Angeles Times..Yet when Dr. Graham told the advisory committee that, based on his research, as few as 10 percent of Rezulin-related adverse events had been reported, members of the panel would have none of it..."

This file is not available for digital download. IRE members may place an order by emailing rescntr@ire.org